Key result
Alternatives to inhaled nitric oxide show potential for managing acute and chronic pulmonary hypertension.
Why the study?
What are the alternative pharmacological agents to inhaled nitric oxide for the management of pulmonary hypertension?
What are the alternative pharmacological agents to inhaled nitric oxide for the management of pulmonary hypertension?
This review highlights various pharmacological alternatives to inhaled nitric oxide, such as prostacyclins and phosphodiesterase inhibitors, for managing pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Supports evaluation of alternatives in pulmonary hypertension; leaves open routine adoption without randomized comparisons.
Inhaled nitric oxide (INO) is a selective pulmonary vasodilator that has the ability to produce vasodilation in the pulmonary vascular bed without causing it in the systemic circulation. This property of INO has made it a useful therapy in the management of both adult and paediatric patients with a variety of conditions associated with pulmonary hypertension (PH), with or without hypoxia. Toxicity, cost and negative-outcome studies have prompted a search for alternative agents. These include inhaled prostacyclin and alternative prostaglandin preparations such as inhaled iloprost, treprostinol and beraprost. The phospodiesterase inhibitors show real potential in the management of both acute and chronic forms of PH, and antagonists of endogenous pulmonary vasoconstrictors, such as endothelin and thromboxane, are being evaluated for the long-term treatment of conditions such as primary pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Stuart M. Lowson (2004) conducted a review in Pulmonary hypertension. Alternatives to inhaled nitric oxide (prostacyclins, phosphodiesterase inhibitors, endothelin antagonists) vs. Inhaled nitric oxide was evaluated. Alternative agents to inhaled nitric oxide, including prostacyclins, phosphodiesterase inhibitors, and endothelin antagonists, show potential for managing acute and chronic pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: